Literature DB >> 9389557

Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round.

M E van den Akker-van Marle1, C M Reep-van den Bergh, R Boer, A Del Moral, N Ascunce, H J de Koning.   

Abstract

Our objective was to evaluate the on-going European pilot project for breast cancer screening in Navarra, Spain, and to predict the effects and costs of the programme in the long run. Observed results in Navarra, consisting of more than 100,000 screens, were compared with expected results. A microsimulation screening analysis model was used that included demographical, epidemiological and screening characteristics of Navarra. Alternative assumptions on epidemiological and screening characteristics were also addressed. The observed detection rate (5.9 per 1,000 screened women) in the first round was 18% higher than expected; the observed rate in the subsequent round (2.9) was 17% lower than expected. Longer pre-clinical durations, lower sensitivity or the existence of a high-risk group in Navarra could not satisfactorily explain the first and second round results together. Nevertheless, the programme will have an important health benefit for the women involved, due to an important trend in incidence in recent years and the relatively unfavourable clinical stage distribution in Navarra. The proportion T2+ cancers that will be prevented after 10 years of screening amounts to 36%. The annual mortality reduction in steady state is expected to range between 17% (if the observed rates in the second round indicate real screening performance) to 23% (if the first round indicates real performance). Our results demonstrate that a high detection rate in the first round is insufficient to evaluate the quality of a programme. Interval cancer rates, results of the subsequent round and size distributions are also crucial indicators of the quality of the screening programme and should be analysed in their specific context.

Entities:  

Mesh:

Year:  1997        PMID: 9389557     DOI: 10.1002/(sici)1097-0215(19971114)73:4<464::aid-ijc2>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study.

Authors:  Per-Henrik Zahl; Bjørn Heine Strand; Jan Maehlen
Journal:  BMJ       Date:  2004-03-10

2.  Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).

Authors:  Misericordia Carles; Ester Vilaprinyo; Francesc Cots; Aleix Gregori; Roger Pla; Rubén Román; Maria Sala; Francesc Macià; Xavier Castells; Montserrat Rue
Journal:  BMC Cancer       Date:  2011-05-23       Impact factor: 4.430

Review 3.  Interpreting overdiagnosis estimates in population-based mammography screening.

Authors:  Rianne de Gelder; Eveline A M Heijnsdijk; Nicolien T van Ravesteyn; Jacques Fracheboud; Gerrit Draisma; Harry J de Koning
Journal:  Epidemiol Rev       Date:  2011-06-27       Impact factor: 6.222

4.  Cost-effectiveness of stereotactic large-core needle biopsy for nonpalpable breast lesions compared to open-breast biopsy.

Authors:  J H Groenewoud; R M Pijnappel; M E van den Akker-Van Marle; E Birnie; T Buijs-van der Woude; W P Th M Mali; H J de Koning; E Buskens
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

5.  Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality.

Authors:  M M Vervoort; G Draisma; J Fracheboud; L V van de Poll-Franse; H J de Koning
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

6.  Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.

Authors:  Arantzazu Arrospide; Montserrat Rue; Nicolien T van Ravesteyn; Merce Comas; Myriam Soto-Gordoa; Garbiñe Sarriugarte; Javier Mar
Journal:  BMC Cancer       Date:  2016-06-01       Impact factor: 4.430

7.  Cost-Effectiveness of Three Rounds of Mammography Breast Cancer Screening in Iranian Women.

Authors:  Shahpar Haghighat; Mohammad Esmaeil Akbari; Parvin Yavari; Mehdi Javanbakht; Shahram Ghaffari
Journal:  Iran J Cancer Prev       Date:  2016-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.